Categories: News Date: Apr 12, 2011 Title: THE BEGINNING OF A NEW ERA IN ANTIBIOTIC DEVELOPMENT
ReAct organized a seminar entitled “The beginning of a new era in antibiotic development: Shaping of a new business model for life-saving innovation” in Brussels on March 29. The seminar was co-hosted with two Members of the European Parliament (Christofer Fjellner, Sweden and Theodoros Skylakakis, Greece), as part of the ongoing efforts to provide constructive input to the current EU deliberations towards both an overall strategy on antibiotic resistance as well as a more specific action plan with focus on the challenge of innovation/development of new antibiotics.
The seminar, moderated by Andrew Jack from the Financial Times, aimed to:
a) Highlight the seriousness of antibiotic resistance
b) Show how lack of innovation/development of new antibiotics is a serious and pressing problem
c) Communicate and further consolidate the understanding that a new paradigm – business model – is needed
d) Reach out to new groups/constituencies to understand their views of the problem
Around 35 participants from different stake-holder groups attended the seminar. Among these were representatives from the European Commission, the pharmaceutical industry, health attachés from several countries and several civil society groups, including MSF, European Patients Forum (EPF), Standing Committee of European Doctors (CPME), Pharmaceutical Group of the European Union (PGEU) and the European Self-Medication Industry (AESGP).
Development of new antibiotics - the industry perspective, Richard Bergström, EFPIA (pdf 360 KB)
An international network to improve the management of antibiotic resistance, Otto Cars, ReAct - Action on Antibiotic Resistance (pdf 663 KB)
Exploring responses to the antibiotics crisis: incentivizing innovation and realigning R&D with medical need, Chantel Morel and Elias Mossialos (pdf 225 KB)
World health day: MEPs call for action on antimicrobial resistance. The Parliament